The combination of photodynamic therapy and intravitreal aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.
Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.